163 related articles for article (PubMed ID: 16931916)
1. The relationship of premature mitosis to cytotoxicity in response to checkpoint abrogation and antimetabolite treatment.
Morgan MA; Parsels LA; Parsels JD; Lawrence TS; Maybaum J
Cell Cycle; 2006 Sep; 5(17):1983-8. PubMed ID: 16931916
[TBL] [Abstract][Full Text] [Related]
2. Role of checkpoint kinase 1 in preventing premature mitosis in response to gemcitabine.
Morgan MA; Parsels LA; Parsels JD; Mesiwala AK; Maybaum J; Lawrence TS
Cancer Res; 2005 Aug; 65(15):6835-42. PubMed ID: 16061666
[TBL] [Abstract][Full Text] [Related]
3. 5-fluoro-2'-deoxyuridine-induced cdc25A accumulation correlates with premature mitotic entry and clonogenic death in human colon cancer cells.
Parsels LA; Parsels JD; Tai DC; Coughlin DJ; Maybaum J
Cancer Res; 2004 Sep; 64(18):6588-94. PubMed ID: 15374972
[TBL] [Abstract][Full Text] [Related]
4. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
[TBL] [Abstract][Full Text] [Related]
5. Differential roles of checkpoint kinase 1, checkpoint kinase 2, and mitogen-activated protein kinase-activated protein kinase 2 in mediating DNA damage-induced cell cycle arrest: implications for cancer therapy.
Xiao Z; Xue J; Sowin TJ; Zhang H
Mol Cancer Ther; 2006 Aug; 5(8):1935-43. PubMed ID: 16928813
[TBL] [Abstract][Full Text] [Related]
6. Targeting the replication checkpoint using SCH 900776, a potent and functionally selective CHK1 inhibitor identified via high content screening.
Guzi TJ; Paruch K; Dwyer MP; Labroli M; Shanahan F; Davis N; Taricani L; Wiswell D; Seghezzi W; Penaflor E; Bhagwat B; Wang W; Gu D; Hsieh Y; Lee S; Liu M; Parry D
Mol Cancer Ther; 2011 Apr; 10(4):591-602. PubMed ID: 21321066
[TBL] [Abstract][Full Text] [Related]
7. Combination drug scheduling defines a "window of opportunity" for chemopotentiation of gemcitabine by an orally bioavailable, selective ChK1 inhibitor, GNE-900.
Blackwood E; Epler J; Yen I; Flagella M; O'Brien T; Evangelista M; Schmidt S; Xiao Y; Choi J; Kowanetz K; Ramiscal J; Wong K; Jakubiak D; Yee S; Cain G; Gazzard L; Williams K; Halladay J; Jackson PK; Malek S
Mol Cancer Ther; 2013 Oct; 12(10):1968-80. PubMed ID: 23873850
[TBL] [Abstract][Full Text] [Related]
8. ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status.
Huntoon CJ; Flatten KS; Wahner Hendrickson AE; Huehls AM; Sutor SL; Kaufmann SH; Karnitz LM
Cancer Res; 2013 Jun; 73(12):3683-91. PubMed ID: 23548269
[TBL] [Abstract][Full Text] [Related]
9. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation.
Xiao Z; Xue J; Sowin TJ; Rosenberg SH; Zhang H
Oncogene; 2005 Feb; 24(8):1403-11. PubMed ID: 15608676
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.
Matthews DJ; Yakes FM; Chen J; Tadano M; Bornheim L; Clary DO; Tai A; Wagner JM; Miller N; Kim YD; Robertson S; Murray L; Karnitz LM
Cell Cycle; 2007 Jan; 6(1):104-10. PubMed ID: 17245119
[TBL] [Abstract][Full Text] [Related]
11. Gemcitabine sensitization by checkpoint kinase 1 inhibition correlates with inhibition of a Rad51 DNA damage response in pancreatic cancer cells.
Parsels LA; Morgan MA; Tanska DM; Parsels JD; Palmer BD; Booth RJ; Denny WA; Canman CE; Kraker AJ; Lawrence TS; Maybaum J
Mol Cancer Ther; 2009 Jan; 8(1):45-54. PubMed ID: 19139112
[TBL] [Abstract][Full Text] [Related]
12. Characterization and preclinical development of LY2603618: a selective and potent Chk1 inhibitor.
King C; Diaz H; Barnard D; Barda D; Clawson D; Blosser W; Cox K; Guo S; Marshall M
Invest New Drugs; 2014 Apr; 32(2):213-26. PubMed ID: 24114124
[TBL] [Abstract][Full Text] [Related]
13. Differential roles for checkpoint kinases in DNA damage-dependent degradation of the Cdc25A protein phosphatase.
Jin J; Ang XL; Ye X; Livingstone M; Harper JW
J Biol Chem; 2008 Jul; 283(28):19322-8. PubMed ID: 18480045
[TBL] [Abstract][Full Text] [Related]
14. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
16. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
[TBL] [Abstract][Full Text] [Related]
17. Chk1-dependent S-M checkpoint delay in vertebrate cells is linked to maintenance of viable replication structures.
Zachos G; Rainey MD; Gillespie DA
Mol Cell Biol; 2005 Jan; 25(2):563-74. PubMed ID: 15632059
[TBL] [Abstract][Full Text] [Related]
18. Chk1 inhibition in p53-deficient cell lines drives rapid chromosome fragmentation followed by caspase-independent cell death.
Del Nagro CJ; Choi J; Xiao Y; Rangell L; Mohan S; Pandita A; Zha J; Jackson PK; O'Brien T
Cell Cycle; 2014; 13(2):303-14. PubMed ID: 24247149
[TBL] [Abstract][Full Text] [Related]
19. Context-dependent cell cycle checkpoint abrogation by a novel kinase inhibitor.
Massey AJ; Borgognoni J; Bentley C; Foloppe N; Fiumana A; Walmsley L
PLoS One; 2010 Oct; 5(10):e13123. PubMed ID: 20976184
[TBL] [Abstract][Full Text] [Related]
20. Knockdown of Chk1 sensitizes human colon carcinoma HCT116 cells in a p53-dependent manner to lidamycin through abrogation of a G2/M checkpoint and induction of apoptosis.
Pan Y; Ren KH; He HW; Shao RG
Cancer Biol Ther; 2009 Aug; 8(16):1559-66. PubMed ID: 19502782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
